Gene variants linked to survival after HSCT

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research has revealed a link between rare gene variants and survival after hematopoietic stem cell transplant (HSCT). Researchers performed exome sequencing in nearly 2500 HSCT recipients and their matched, unrelated donors. The sequencing revealed several gene variants—in both donors and recipients—that were significantly associated with overall survival... [Read Article]
Print Friendly, PDF & Email

Health Canada approves product for adult ALL

Print Friendly, PDF & Email


Micrograph showing ALL
Health Canada has approved inotuzumab ozogamicin (Besponsa™) as monotherapy for adults with relapsed or refractory, CD22-positive, B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin is the first and only CD22-directed antibody-drug conjugate approved for this indication. The product consists of a monoclonal antibody targeting CD22 and a cytotoxic agent known as calicheamicin.... [Read Article]
Print Friendly, PDF & Email

Team maps genetic evolution of T-ALL subtype

Print Friendly, PDF & Email


Bone marrow smear of T-ALL
© Hind Medyouf, German
Cancer Research Center
Single-cell analysis has revealed key genetic events in a type of T-cell acute lymphoblastic leukemia (T- ALL), according to researchers. The team tracked the branching pattern of evolution in STIL-TAL1-positive T-ALL and identified mutations that may trigger development of the disease. The researchers... [Read Article]
Print Friendly, PDF & Email

FDA approves blinatumomab to treat MRD+ BCP-ALL

Print Friendly, PDF & Email


Vials of blinatumomab powder
and solution for infusion
Photo courtesy of Amgen
The US Food and Drug Administration (FDA) has expanded the approved indication for blinatumomab (Blincyto®). The drug is now approved to treat adults and children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in first or second complete remission (CR) with minimal residual... [Read Article]
Print Friendly, PDF & Email

Disease, genetics contribute to neurocognitive decline in ALL

Print Friendly, PDF & Email


Kevin Krull, PhD (left)
and Yin Ting Cheung, PhD
Photo by Seth Dixon/
St. Jude Children’s
Research Hospital
Chemotherapeutic agents have been associated with neurocognitive side effects in survivors of pediatric acute lymphoblastic leukemia (ALL). Now, researchers have found evidence to suggest that genetics and ALL itself can increase the risk for long-term problems... [Read Article]
Print Friendly, PDF & Email

UCART19 can bridge to transplant in adults

Print Friendly, PDF & Email


T cells
Image from NIAID
Preliminary data from a phase 1 trial suggest UCART19 can serve as a bridge to transplant in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). This “universal,” donor-derived, chimeric antigen receptor (CAR) T-cell therapy produced complete responses (CRs) in 6 of 9 patients treated. Five of the patients... [Read Article]
Print Friendly, PDF & Email

Phase 1 results with UCART19 in kids

Print Friendly, PDF & Email


Layla Richards, the first person
treated with UCART19
Photo courtesy of GOSH
Early results from a phase 1, pediatric trial of UCART19 expand upon results observed in children who received the therapy via a compassionate use program. Two patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) received UCART19, a “universal,” donor-derived chimeric antigen... [Read Article]
Print Friendly, PDF & Email

ICER assesses value of CAR T-cell therapies

Print Friendly, PDF & Email


Tisagenlecleucel (Kymriah)
Photo from Novartis
The Institute for Clinical and Economic Review (ICER) has made policy recommendations intended to ensure affordability and access to chimeric antigen receptor (CAR) T-cell therapies. ICER released a Final Evidence Report on tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead), 2 CAR T-cell therapies approved in the US... [Read Article]
Print Friendly, PDF & Email